USA-based biotech Ajax Therapeutics today announced the completion of an oversubscribed $95 million Series C financing, led by Goldman Sachs with participation from new investors, including Eli Lilly (NYSE: LLY), and existing investors.
The company also announced it has received US Food and Drug Administration (FDA) clearance of its investigational new drug (IND) application for lead candidate AJ1-11095, a first-in-class Type II JAK2 inhibitor myelofibrosis.
With the FDA clearance of its IND, Ajax noted that AJ1-11095 will be the first Type II JAK2 Inhibitor to enter the clinic – with a Phase I study in myelofibrosis planned to begin in 2H 2024.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze